11,987 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by DRW Securities LLC

DRW Securities LLC acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 11,987 shares of the biotechnology company’s stock, valued at approximately $74,000.

Several other institutional investors also recently bought and sold shares of BCRX. Vanguard Group Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 15.4% in the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock valued at $106,405,000 after acquiring an additional 2,371,401 shares in the last quarter. Norges Bank acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at about $13,278,000. Rafferty Asset Management LLC boosted its holdings in BioCryst Pharmaceuticals by 18.3% in the 4th quarter. Rafferty Asset Management LLC now owns 955,587 shares of the biotechnology company’s stock valued at $5,724,000 after purchasing an additional 147,699 shares in the last quarter. ProShare Advisors LLC increased its position in BioCryst Pharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company’s stock worth $246,000 after purchasing an additional 4,041 shares during the period. Finally, Braidwell LP raised its stake in shares of BioCryst Pharmaceuticals by 6.6% during the 4th quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock worth $34,254,000 after buying an additional 355,497 shares in the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Down 2.1 %

BioCryst Pharmaceuticals stock opened at $7.63 on Wednesday. The firm’s 50-day simple moving average is $7.81 and its 200 day simple moving average is $6.40. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $8.88. The firm has a market capitalization of $1.57 billion, a PE ratio of -7.13 and a beta of 1.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.11. The business had revenue of $109.30 million during the quarter, compared to analyst estimates of $98.30 million. During the same quarter in the prior year, the company earned ($0.24) earnings per share. The firm’s revenue for the quarter was up 34.9% compared to the same quarter last year. On average, research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Barclays lifted their price target on BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. JMP Securities raised their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. Finally, StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $14.17.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.